SynthesisFrontiers in medicine2026
Efficacy and safety of telitacicept in adults with systemic lupus erythematosus: a systematic review and stratified meta-analysis.
Synthesis in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Telitacicept is a TACI-Fc fusion protein that targets both B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL). Evidence in adults with systemic lupus erythematosus (SLE) includes placebo-controlled randomized trials, other comparative studies, and single-arm cohorts. Objectives: To assess the efficacy and safety of telitacicept in adults with SLE and to synthesize placebo-controlled randomized trials, other comparative studies, and single-arm treatment cohorts separately by study design. Methods: We searched electronic databases, screened references, and conducted hand searches, and cross-checked international trial registries. Eligible studies enrolled adults with SLE, including lupus nephritis (LN) subgroups. Comparative binary outcomes were pooled as risk ratios (RRs), continuous outcomes as mean differences (MDs), and single-arm outcomes as logit-transformed proportions. Random-effects models were used, and evidence certainty was assessed using GRADE. Results: Thirty-nine reports, all from China, were included, and 22 contributed to quantitative synthesis. In two placebo-controlled randomized trials, telitacicept 160 mg plus standard therapy increased SLE Responder Index-4 (SRI-4) response at 48-52 weeks (RR = 2.04, 95% CI 1.66-2.50; I2 = 0.0%) and slightly increased any adverse events (RR = 1.09, 95% CI 1.02-1.17). No clear difference was observed for serious adverse events (RR = 0.68, 95% CI 0.35-1.30). Observational comparative findings in adult LN and single-arm cohort proportions were assessed separately. GRADE rated SRI-4 response and any adverse event as moderate certainty, serious adverse events as low certainty, and all other outcomes as very low certainty. Conclusion: In the Chinese populations studied, telitacicept 160 mg plus standard therapy probably improves SRI-4 response at 48-52 weeks in adults with active SLE and may slightly increase any adverse events. Evidence for other outcomes is uncertain and does not establish comparative efficacy or long-term safety. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261464193, PROSPERO CRD420261464193.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.